ClinicalTrials.gg
CompletedNCT01613326GLOW5Updated Apr 23, 2014Results posted

Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of NVA237 and Tiotropium in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 76 sites in 15 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-04-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
657
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
18th of 73
657 · median 152
Started
2012
with 10 others
Phase 3
33 of 73
1 open now
Registered
21st of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 18th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 21st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This study compared the efficacy and safety of NVA237 with tiotropium in patients with moderate to severe COPD. Tiotropium belongs to the same drug class as NVA237.

Read the detailed description

This was a randomized, blinded, double-dummy, parallel-group 12-week study to assess the efficacy, safety, and tolerability of NVA237 (50 μg o.d.) compared to tiotropium (18 μg o.d.) in patients with chronic obstructive pulmonary disease (COPD).

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • COPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with moderate to severe stable (Stage II or Stage III) according to the current GOLD Guidelines (GOLD 2010).
  • Patients with a post-bronchodilator (FEV1) ≥ 30% and \< 80% of the predicted normal, and a post-bronchodilator FEV1/ Forced Vital Capacity (FVC) \< 0.70 at screening
  • Current or ex-smokers who have a smoking history of at least 10 pack years (e.g. 10 pack years = 1 pack/day x 10 yrs, or ½ pack/day x 20 yrs).
  • Symptomatic patients, according to daily electronic diary data between Visit 2 (Day -14) and Visit 3 (Day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to Visit 3.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing (lactating) women
  • Patients who, in the judgment of the investigator, or the responsible Novartis personnel, have a laboratory abnormality or a clinically significant condition before Visit 1.
  • Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or urinary retention. (BPH patients who are stable on treatment can be considered).
  • Patients receiving medications in the classes listed in the protocol as prohibited.

Other protocol-defined inclusion/exclusion criteria apply and can be found in the study protocol

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
657 participants (actual)

Study arms

  • Experimental
    NVA237

    NVA237 50 μg once a day and placebo to tiotropium once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.

    Drug: NVA237 · Drug: Placebo to tiotropium · Drug: salbutamol/albuterol

  • Active comparator
    Tiotropium

    Tiotropium 18 μg once a day and placebo to NVA237 once a day during 85 days. Salbutamol/albuterol was provided as rescue medication.

    Drug: Tiotropium · Drug: Placebo to NVA237

Interventions

  • DrugNVA237

    NVA237 50 μg inhalation capsules once a day, delivered via SDDPI

  • Tiotropium 18 μg once a day delivered via HandiHaler® device

  • DrugPlacebo to tiotropium

    Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.

  • DrugPlacebo to NVA237

    Placebo to NVA237 50 μg once a day delivered via SDDPI

  • Drugsalbutamol/albuterol

    Drug page: Albuterol

    salbutamol/albuterol given as a rescue medication via inhaler when needed

06

What researchers measure

Primary outcomes

  1. Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis)

    Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23hours 15min and 23 hours 45min post dosing. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region). This analysis excluded values within 6 hours of rescue medication use or 7 days of systemic corticosteroid use.

    Time frame: Week 12

Secondary outcomes

  1. Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Analysis of Superiority)

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). This analysis excluded values within 6 hours of rescue medication use or 7 days of systemic corticosteroid.

    Time frame: Week 12

  2. Transition Dyspnea Index (TDI) Focal Score After 4 Weeks and 12 Weeks of Treatment

    Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. ANCOVA model: TDI focal score = treatment + Baseline dyspnea index (BDI) + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

    Time frame: Weeks 4 and 12

  3. St. George's Respiratory Questionnaire Total Score After 12 Weeks of Treatment

    St. George's Respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire consisting of 51 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status. ANCOVA model: SGRQ total score = treatment + baseline SGRQ score + baseline ICS use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region).

    Time frame: Week 12

  4. Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 12 Week Treatment

    A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. Baseline mean daily, daytime and nighttime (combined) number of puffs is defined as the average of the respective number of puffs. Only patients with a value at both baseline and post-baseline visits were included.

    Time frame: Baseline and Day 1 to Week 12

  5. Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 4

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Trough FEV1 is defined as the average of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. Trough assessments taken outside 22 h 45 min - 24 h 15 min are excluded from this analysis. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

    Time frame: Day 1 and Week 4

  6. Peak Forced Expiratory Volume in 1 Second (FEV1) During 5 Min to 4 Hours Post-dose, at Day 1 and Week 12

    Spirometry was conducted according to internationally accepted standards. Peak FEV1 is the maximum FEV1 recorded during first 4 hours post dose. ANCOVA model: Peak FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region). Center is included as a random effect nested within region. This analysis excludes values within 6 hours of rescue medication use or 7 days of systemic corticosteroid use.

    Time frame: 5 min to 4 hours post-dose at Day 1 and Week 12

  7. Inspiratory Capacity (IC) at Each Time-point, by Visit

    IC was measured with spirometry conducted according to internationally accepted standards. ANCOVA model: IC = treatment + baseline IC + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

    Time frame: (25 min, 1 h 55 min, 3 h 55 min, 23 h 40 min Day 1), (-20 min, 25 min, 23 h 40 min Week 4),(-20 min, 25 min, 1 h 55 min, 3 h 55 min, 23 h 40 min Week 12)

  8. Forced Expiratory Volume in 1 Second (FEV1) at Each Time-point by Visit

    Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 was analyzed using Analysis of Covariance (ANCOVA) model: FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

    Time frame: (5,15,30 min, 1, 2,3,4 h, 23h 15 min and 23h 45 min postdose of Day 1), (-45, -15 min predose, 5,15,30 min, 1h, 23h 15 min and 23h 45 min postdose of Week 4), (-45, -15 min predose, 5,15,30 min, 1, 2, 3,4 h, 23h 15 min and 23h 45 min postdose of Week 12)

  9. Forced Vital Capacity (FVC) at Each Time-point by Visit

    Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. ANCOVA model: FVC = treatment + baseline FVC + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

    Time frame: (5,15,30 min, 1, 2,3,4 h, 23h 15 min and 23h 45 min postdose of Day 1), (-45, -15 min predose, 5,15,30 min, 1h, 23h 15 min and 23h 45 min postdose of Week 4), (-45, -15 min predose, 5,15,30 min, 1, 2, 3,4 h, 23h 15 min and 23h 45 min postdose of Week 12)

  10. Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (5 Min-4 h) Post-dose

    Forced Expiratory Volume in one second (FEV1) was measured with spirometry conducted according to internationally accepted standards. Area Under the Curve (AUC) is calculated using the trapezoidal rule using the existing FEV1 measurements (i.e., the missing FEV1 measurements are not interpolated). ANCOVA model: FEV1 AUC = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

    Time frame: Day 1 and week 12

  11. Event Free Rate at Weeks 4, 8 and 12 After Treatment

    Event free rate was calculated as a percentage of participants who did not experience any moderate or severe COPD exacerbation leading to hospitalization/treatment with systemic corticosteroids/treatment with antibiotics. The event free rate reflects the percent of patients who did NOT have an exacerbation by 4, 8 and 12 weeks. Event-free rates are calculated at the end of the specified weeks (i.e. Day 29, Day 57 and Day 85) by the Kaplan Meier method.

    Time frame: Weeks 4, 8 and 12

  12. Mean Daily, Daytime and Nighttime (Combined) Symptom Scores Over the 12 Week Treatment Period

    Participants completed eDiaries providing scores 0 to 3 for symptoms: Cough and wheeze (none, mild, moderate, severe); sputum volume (none, less than 5 mL, 5-25 mL, \>25 mL); sputum color (none, white-grey, yellow, green); lowest level of activity causing breathlessness (never or only when running, when walking uphill or upstairs, when walking on flat ground, at rest). Symptoms in the morning, for the previous night (no waking due to symptoms, woke up once due to symptoms, woke up more than once due to symptoms, woke up frequently or could not sleep due to symptoms). Symptoms experienced during the day that had prevented them for performing normal activities (not at all, a little, quite a lot, completely). The mean change from baseline in the total scores and in the individual scores was summarized by treatment. Only participants with a value at both baseline and post-baseline were included. Possible total scores 0-18 (night); 0-36 (day). A higher score means worsening of symptoms.

    Time frame: 12 weeks

07

Results

Posted Apr 23, 2014

Participant flow

A total of 980 patients were screened, and 657 were randomized (327 to NVA237 and 330 to tiotropium).

Participant flow — Overall Study
MilestoneNVA237Tiotropium
Started327330
Completed314316
Not completed1314
Withdrew: Adverse event75
Withdrew: Withdrawal by subject34
Withdrew: Abnormal test procedure result(s)20
Withdrew: Inability to use device10
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up01
Withdrew: Administrative02
Withdrew: Protocol violation01

Outcome measures

PrimaryTrough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis)

Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23hours 15min and 23 hours 45min post dosing. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region). This analysis excluded values within 6 hours of rescue medication use or 7 days of systemic corticosteroid use.

Time frame:
Week 12
Reported as:
Least squares mean · Liters
Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis)
LitersNVA237Tiotropium
Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis)1.405 ± 0.01731.405 ± 0.0170
SecondaryTrough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Analysis of Superiority)

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. The trough in FEV1 was defined as the mean of two measurements at 23h 15min and 23h 45min post dosing. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). This analysis excluded values within 6 hours of rescue medication use or 7 days of systemic corticosteroid.

Time frame:
Week 12
Reported as:
Least squares mean · Liters
Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Analysis of Superiority)
LitersNVA237Tiotropium
Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Analysis of Superiority)1.398 ± 0.01541.393 ± 0.0149
SecondaryTransition Dyspnea Index (TDI) Focal Score After 4 Weeks and 12 Weeks of Treatment

Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline. ANCOVA model: TDI focal score = treatment + Baseline dyspnea index (BDI) + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

Time frame:
Weeks 4 and 12
Reported as:
Least squares mean · Units on a scale
Transition Dyspnea Index (TDI) Focal Score After 4 Weeks and 12 Weeks of Treatment
Units on a scaleNVA237Tiotropium
Week 4 (n= 289, 287)2.209 ± 0.29572.086 ± 0.2945
Week 12 (n= 290, 285)1.990 ± 0.31692.178 ± 0.3159
SecondarySt. George's Respiratory Questionnaire Total Score After 12 Weeks of Treatment

St. George's Respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire consisting of 51 items in three areas: symptoms (respiratory symptoms and severity), activity (activities that cause or are limited by breathlessness) and impacts (social functioning and psychological disturbances due to airway disease). The total score is 0 to 100 with a higher score indicating poorer health status. ANCOVA model: SGRQ total score = treatment + baseline SGRQ score + baseline ICS use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region).

Time frame:
Week 12
Reported as:
Least squares mean · Units on a scale
St. George's Respiratory Questionnaire Total Score After 12 Weeks of Treatment
Units on a scaleNVA237Tiotropium
St. George's Respiratory Questionnaire Total Score After 12 Weeks of Treatment39.42 ± 1.31338.77 ± 1.306
SecondaryChange From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 12 Week Treatment

A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. Baseline mean daily, daytime and nighttime (combined) number of puffs is defined as the average of the respective number of puffs. Only patients with a value at both baseline and post-baseline visits were included.

Time frame:
Baseline and Day 1 to Week 12
Reported as:
Mean · puffs
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication Used Over the 12 Week Treatment
puffsNVA237Tiotropium
Baseline4.09 ± 3.8164.10 ± 3.791
Day 1 to week 122.76 ± 2.7682.84 ± 2.934
SecondaryTrough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 4

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Trough FEV1 is defined as the average of the post-dose 23 h 15 min and the 23 h 45 min FEV1 values. Trough assessments taken outside 22 h 45 min - 24 h 15 min are excluded from this analysis. ANCOVA model: Trough FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

Time frame:
Day 1 and Week 4
Reported as:
Least squares mean · Liters
Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Week 4
LitersNVA237Tiotropium
Day 1 (n=296, 288)1.385 ± 0.01241.386 ± 0.0122
Week 4 (n=284, 280)1.416 ± 0.01631.416 ± 0.0160
SecondaryPeak Forced Expiratory Volume in 1 Second (FEV1) During 5 Min to 4 Hours Post-dose, at Day 1 and Week 12

Spirometry was conducted according to internationally accepted standards. Peak FEV1 is the maximum FEV1 recorded during first 4 hours post dose. ANCOVA model: Peak FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center (region). Center is included as a random effect nested within region. This analysis excludes values within 6 hours of rescue medication use or 7 days of systemic corticosteroid use.

Time frame:
5 min to 4 hours post-dose at Day 1 and Week 12
Reported as:
Least squares mean · Liters
Peak Forced Expiratory Volume in 1 Second (FEV1) During 5 Min to 4 Hours Post-dose, at Day 1 and Week 12
LitersNVA237Tiotropium
Day 1 (n= 298, 292)1.575 ± 0.01231.520 ± 0.0121
Week 12 (n= 290, 282)1.577 ± 0.01661.553 ± 0.0163
SecondaryInspiratory Capacity (IC) at Each Time-point, by Visit

IC was measured with spirometry conducted according to internationally accepted standards. ANCOVA model: IC = treatment + baseline IC + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

Time frame:
(25 min, 1 h 55 min, 3 h 55 min, 23 h 40 min Day 1), (-20 min, 25 min, 23 h 40 min Week 4),(-20 min, 25 min, 1 h 55 min, 3 h 55 min, 23 h 40 min Week 12)
Reported as:
Least squares mean · Liters
Inspiratory Capacity (IC) at Each Time-point, by Visit
LitersNVA237Tiotropium
Day 1, 25 min (n= 216, 214)2.378 ± 0.02632.300 ± 0.0253
Day 1, 1 h 55 min (n= 212, 208)2.433 ± 0.03132.335 ± 0.0298
Day 1, 3 h 55 min (n= 211, 207)2.343 ± 0.03252.309 ± 0.0317
Day 1, 23 h 40 min (n= 213, 212)2.247 ± 0.03062.244 ± 0.0294
Week 4, -20 min (n= 204, 204)2.231 ± 0.03422.240 ± 0.0326
Week 4, 25 min (n= 201, 200)2.335 ± 0.03302.334 ± 0.0312
Week 4, 23 h 40 min (n=199,205)2.284 ± 0.03622.289 ± 0.0347
Week 12, -20 min (n= 205, 204)2.198 ± 0.04082.227 ± 0.0394
Week 12, 25 min (n= 215, 205)2.292 ± 0.03972.280 ± 0.0385
Week 12, 1 h 55 min (n= 213, 203)2.344 ± 0.04322.289 ± 0.0421
Week 12, 3 h 55 min (n= 203, 207)2.313 ± 0.03952.275 ± 0.0374
Week 12, 23 h 40 min (n= 208, 206)2.228 ± 0.03902.262 ± 0.0373
SecondaryForced Expiratory Volume in 1 Second (FEV1) at Each Time-point by Visit

Forced Expiratory Volume in 1 second (FEV1) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. FEV1 was analyzed using Analysis of Covariance (ANCOVA) model: FEV1 = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

Time frame:
(5,15,30 min, 1, 2,3,4 h, 23h 15 min and 23h 45 min postdose of Day 1), (-45, -15 min predose, 5,15,30 min, 1h, 23h 15 min and 23h 45 min postdose of Week 4), (-45, -15 min predose, 5,15,30 min, 1, 2, 3,4 h, 23h 15 min and 23h 45 min postdose of Week 12)
Reported as:
Least squares mean · Liters
Forced Expiratory Volume in 1 Second (FEV1) at Each Time-point by Visit
LitersNVA237Tiotropium
Day 1, 5 min (n= 283, 278)1.382 ± 0.00871.331 ± 0.0086
Day 1, 15 min (n= 282, 276)1.428 ± 0.00861.365 ± 0.0084
Day 1, 30 min (n= 285, 281)1.442 ± 0.01041.379 ± 0.0102
Day 1, 1 hour (n= 291, 286)1.482 ± 0.01111.419 ± 0.0109
Day 1, 2 hours (n= 290, 286)1.517 ± 0.01271.454 ± 0.0126
Day 1, 3 hours (n= 291, 285)1.527 ± 0.01411.471 ± 0.0138
Day 1, 4 hours (n= 285, 281)1.490 ± 0.01371.448 ± 0.0135
Day 1, 23 h 15 min (n= 289, 279)1.384 ± 0.01271.384 ± 0.0124
Day 1, 23 h 45 min (n= 285, 278)1.381 ± 0.01391.379 ± 0.0140
Week 4, -45 min (n= 280, 280)1.403 ± 0.01451.391 ± 0.0140
Week 4, -15 min (n= 278, 279)1.388 ± 0.01461.393 ± 0.0139
Week 4, 5 min (n= 277, 274)1.422 ± 0.01651.423 ± 0.0160
Week 4, 15 min (n= 271, 270)1.459 ± 0.01631.466 ± 0.0159
Week 4, 30 min (n= 272, 276)1.454 ± 0.01791.442 ± 0.0175
Week 4, 1 hr (n= 280, 282)1.513 ± 0.01521.494 ± 0.0147
Week 4, 23 h 15 min (n= 278, 276)1.422 ± 0.01711.417 ± 0.0167
Week 4, 23 h 45 min (n= 274, 276)1.418 ± 0.01651.416 ± 0.0162
Week 12, -45 min (n= 286, 279)1.394 ± 0.01761.380 ± 0.0174
Week 12, -15 min (n= 283, 279)1.377 ± 0.01681.370 ± 0.0165
Week 12, 5 min (n= 283, 271)1.430 ± 0.01821.411 ± 0.0181
Week 12, 15 min (n= 275, 271)1.440 ± 0.01681.423 ± 0.0163
Week 12, 30 min (n= 282, 278)1.461 ± 0.01681.432 ± 0.0163
Week 12, 1 hr (n= 286, 279)1.500 ± 0.01641.475 ± 0.0160
Week 12, 2 hours (n= 278, 277)1.507 ± 0.01731.484 ± 0.0169
Week 12, 3 hours (n= 281, 279)1.506 ± 0.01791.484 ± 0.0175
Week 12, 4 hours (n= 282, 280)1.473 ± 0.01871.462 ± 0.0183
Week 12, 23 h 15 min (n= 276, 266)1.414 ± 0.01851.422 ± 0.0183
Week 12, 23 h 45 min (n= 278, 276)1.415 ± 0.01831.420 ± 0.0180
SecondaryForced Vital Capacity (FVC) at Each Time-point by Visit

Forced Vital Capacity (FVC) is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. FVC was assessed via spirometry. ANCOVA model: FVC = treatment + baseline FVC + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

Time frame:
(5,15,30 min, 1, 2,3,4 h, 23h 15 min and 23h 45 min postdose of Day 1), (-45, -15 min predose, 5,15,30 min, 1h, 23h 15 min and 23h 45 min postdose of Week 4), (-45, -15 min predose, 5,15,30 min, 1, 2, 3,4 h, 23h 15 min and 23h 45 min postdose of Week 12)
Reported as:
Least squares mean · Liters
Forced Vital Capacity (FVC) at Each Time-point by Visit
LitersNVA237Tiotropium
Day 1, 5 min (n= 283, 278)2.925 ± 0.02492.874 ± 0.0247
Day 1, 15 min (n= 282, 276)3.004 ± 0.02812.954 ± 0.0280
Day 1, 30 min (n= 285, 281)3.036 ± 0.02772.991 ± 0.0274
Day 1, 1 hour (n= 291, 286)3.036 ± 0.02983.006 ± 0.0296
Day 1, 2 hours (n= 290, 286)3.061 ± 0.03143.029 ± 0.0312
Day 1, 3 hours (n= 291, 285)3.135 ± 0.03343.111 ± 0.0329
Day 1, 4 hours (n= 285, 281)3.073 ± 0.03053.046 ± 0.0301
Day 1, 23 h 15 min (n= 289, 279)2.911 ± 0.02872.951 ± 0.0284
Day 1, 23 h 45 min (n= 285, 278)2.942 ± 0.02792.951 ± 0.0279
Week 4, -45 min (n= 280, 280)2.933 ± 0.03382.943 ± 0.0331
Week 4, -15 min (n= 278, 279)2.879 ± 0.03562.898 ± 0.0345
Week 4, 5 min (n= 277, 274)2.954 ± 0.03632.997 ± 0.0354
Week 4, 15 min (n= 271, 270)3.021 ± 0.03783.058 ± 0.0372
Week 4, 30 min (n= 272, 276)3.005 ± 0.04133.011 ± 0.0407
Week 4, 1 hr (n= 280, 282)3.068 ± 0.03813.093 ± 0.0374
Week 4, 23 h 15 min (n= 278, 276)2.982 ± 0.03643.013 ± 0.0359
Week 4, 23 h 45 min (n= 274, 276)2.953 ± 0.03722.978 ± 0.0366
Week 12, -45 min (n= 286, 279)2.889 ± 0.04162.905 ± 0.0415
Week 12, -15 min (n= 283, 279)2.827 ± 0.03582.837 ± 0.0355
Week 12, 5 min (n= 283, 271)2.929 ± 0.04032.953 ± 0.0403
Week 12, 15 min (n= 275, 271)2.945 ± 0.03702.963 ± 0.0364
Week 12, 30 min (n= 282, 278)2.963 ± 0.03742.982 ± 0.0367
Week 12, 1 hr (n= 286, 279)3.011 ± 0.03773.009 ± 0.0373
Week 12, 2 hours (n= 278, 277)3.008 ± 0.03903.012 ± 0.0386
Week 12, 3 hours (n= 281, 279)3.014 ± 0.04043.018 ± 0.0399
Week 12, 4 hours (n= 282, 280)2.964 ± 0.04042.977 ± 0.0398
Week 12, 23 h 15 min (n= 276, 266)2.923 ± 0.04032.953 ± 0.0404
Week 12, 23 h 45 min (n= 278, 276)2.929 ± 0.04362.955 ± 0.0434
SecondaryStandardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (5 Min-4 h) Post-dose

Forced Expiratory Volume in one second (FEV1) was measured with spirometry conducted according to internationally accepted standards. Area Under the Curve (AUC) is calculated using the trapezoidal rule using the existing FEV1 measurements (i.e., the missing FEV1 measurements are not interpolated). ANCOVA model: FEV1 AUC = treatment + baseline FEV1 + baseline Inhaled corticosteroid (ICS) use (Yes/No) + FEV1 reversibility components + baseline smoking status + region + center(region). Center is included as a random effect nested within region.

Time frame:
Day 1 and week 12
Reported as:
Least squares mean · Liters
Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (5 Min-4 h) Post-dose
LitersNVA237Tiotropium
Day 1 (n=298, 292)1.496 ± 0.01091.438 ± 0.0107
Week 12 (290, 282)1.493 ± 0.01641.470 ± 0.0160
SecondaryEvent Free Rate at Weeks 4, 8 and 12 After Treatment

Event free rate was calculated as a percentage of participants who did not experience any moderate or severe COPD exacerbation leading to hospitalization/treatment with systemic corticosteroids/treatment with antibiotics. The event free rate reflects the percent of patients who did NOT have an exacerbation by 4, 8 and 12 weeks. Event-free rates are calculated at the end of the specified weeks (i.e. Day 29, Day 57 and Day 85) by the Kaplan Meier method.

Time frame:
Weeks 4, 8 and 12
Reported as:
Number · percentage of participants
Event Free Rate at Weeks 4, 8 and 12 After Treatment
percentage of participantsNVA237Tiotropium
Week 495.6 (92.6 to 97.4)96.6 (93.7 to 98.1)
Week 892.9 (89.3 to 95.3)93.8 (90.4 to 96.1)
Week 1290.2 (86.1 to 93.2)92.4 (88.8 to 95.0)
SecondaryMean Daily, Daytime and Nighttime (Combined) Symptom Scores Over the 12 Week Treatment Period

Participants completed eDiaries providing scores 0 to 3 for symptoms: Cough and wheeze (none, mild, moderate, severe); sputum volume (none, less than 5 mL, 5-25 mL, \>25 mL); sputum color (none, white-grey, yellow, green); lowest level of activity causing breathlessness (never or only when running, when walking uphill or upstairs, when walking on flat ground, at rest). Symptoms in the morning, for the previous night (no waking due to symptoms, woke up once due to symptoms, woke up more than once due to symptoms, woke up frequently or could not sleep due to symptoms). Symptoms experienced during the day that had prevented them for performing normal activities (not at all, a little, quite a lot, completely). The mean change from baseline in the total scores and in the individual scores was summarized by treatment. Only participants with a value at both baseline and post-baseline were included. Possible total scores 0-18 (night); 0-36 (day). A higher score means worsening of symptoms.

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Mean Daily, Daytime and Nighttime (Combined) Symptom Scores Over the 12 Week Treatment Period
units on a scaleNVA237Tiotropium
Baseline7.21 ± 2.5396.90 ± 2.627
Day 1 to Week 125.96 ± 2.4695.96 ± 2.531

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237—11/327 (3.4%)48/327 (14.7%)
Tiotropium—13/330 (3.9%)54/330 (16.4%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventNVA237Tiotropium
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders3/3276/330
PneumoniaInfections and infestations2/3272/330
Ischaemic strokeNervous system disorders0/3272/330
Cardiac failureCardiac disorders1/3270/330
Diverticulum intestinalGastrointestinal disorders1/3270/330
Non-cardiac chest painGeneral disorders1/3270/330
CellulitisInfections and infestations1/3270/330
Lobar pneumoniaInfections and infestations1/3270/330
Femur fractureInjury, poisoning and procedural complications1/3270/330
Spinal cord injury cervicalInjury, poisoning and procedural complications1/3270/330
Most frequent other events
Most frequent other events
EventNVA237Tiotropium
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders48/32754/330

Baseline characteristics

Age, Continuous
Age, Continuous(Years)NVA237TiotropiumTotal
Mean63.2 ± 7.9863.7 ± 8.0263.5 ± 8.00
Sex: Female, Male
Sex: Female, Male(Participants)NVA237TiotropiumTotal
Female9082172
Male237248485
08

Study locations

76 sites
  • Novartis Investigative Site
    Toronto, Ontario M5G1N8, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5T 3A9, Canada
  • Novartis Investigative Site
    Toronto, Ontario M6H 3M2, Canada
  • Novartis Investigative Site
    Gatineau, Quebec J8Y 6S8, Canada
  • Novartis Investigative Site
    Mirabel, Quebec J7J 2K8, Canada
  • Novartis Investigative Site
    St-Charles-Borromée, Quebec J6E 6J2, Canada
  • Novartis Investigative Site
    Sisak, 44000, Croatia
  • Novartis Investigative Site
    Zagreb, 10 000, Croatia
  • Novartis Investigative Site
    Zagreb, 10000, Croatia
  • Novartis Investigative Site
    Cvikov, 471 54, Czech Republic
  • Novartis Investigative Site
    Liberec, 460 01, Czech Republic
  • Novartis Investigative Site
    Praha 10, 108 00, Czech Republic
  • Novartis Investigative Site
    Praha 4, 140 46, Czech Republic
  • Novartis Investigative Site
    Praha 6, 169 00, Czech Republic
  • Novartis Investigative Site
    Rudna, 25219, Czech Republic
  • Novartis Investigative Site
    Teplice, 415 01, Czech Republic
  • Novartis Investigative Site
    Zatec, 438 01, Czech Republic
  • Novartis Investigative Site
    Paide, 72714, Estonia
  • Novartis Investigative Site
    Tallinn, 13419, Estonia
  • Novartis Investigative Site
    Tallinn, 13619, Estonia
  • Novartis Investigative Site
    Tartu, 51014, Estonia
  • Novartis Investigative Site
    Beuvry, 62660, France
  • Novartis Investigative Site
    Lyon cedex 04, 69317, France
  • Novartis Investigative Site
    Nantes, 44000, France
  • Novartis Investigative Site
    Reims, 51092, France
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Berlin, 14050, Germany
  • Novartis Investigative Site
    Frankfurt, 60596, Germany
  • Novartis Investigative Site
    Hamburg, 20253, Germany
  • Novartis Investigative Site
    Kassel, 34121, Germany
  • Novartis Investigative Site
    Leipzig, 04207, Germany
  • Novartis Investigative Site
    Potsdam, 14478, Germany
  • Novartis Investigative Site
    Rüdersdorf, 15562, Germany
  • Novartis Investigative Site
    Wiesbaden, 65187, Germany
  • Novartis Investigative Site
    Guatemala City, 01010, Guatemala
  • Novartis Investigative Site
    Guatemala City, 01011, Guatemala
  • Novartis Investigative Site
    Guntur, Andhra Pradesh 522 001, India
  • Novartis Investigative Site
    Ahmedabad, Gujarat 380 009, India
  • Novartis Investigative Site
    Bangalore, Karnataka 560 010, India
  • Novartis Investigative Site
    Nagpur, Maharashtra, India
  • Novartis Investigative Site
    Coimbatore, Tamil Nadu 641 045, India
  • Novartis Investigative Site
    Coimbatore, Tamil Nadu 641014, India
  • Novartis Investigative Site
    Chennai - Tamil Nadu, 600 087, India
  • Novartis Investigative Site
    Bucheon-Si, Gyeonggi-Do, Korea, Republic of
  • Novartis Investigative Site
    Busan, 602-739, Korea, Republic of
  • Novartis Investigative Site
    Daegu, 705-717, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 130-702, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 130-709, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 152-703, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 156-755, Korea, Republic of
  • Novartis Investigative Site
    Daugavpils, LV-5401, Latvia
  • Novartis Investigative Site
    Riga, 1002, Latvia
  • Novartis Investigative Site
    Alytus, LT-62114, Lithuania
  • Novartis Investigative Site
    Kaunas, LT-47144, Lithuania
  • Novartis Investigative Site
    Klaipeda, 92288, Lithuania
  • Novartis Investigative Site
    Klaipeda, LT-92231, Lithuania
  • Novartis Investigative Site
    Utena, LT-28151, Lithuania
  • Novartis Investigative Site
    Vilnius, 06001, Lithuania
  • Novartis Investigative Site
    Vilnius, LT-08661, Lithuania
  • Novartis Investigative Site
    Lipa City, Batangas 4217, Philippines
  • Novartis Investigative Site
    Bulacan, 3020, Philippines
  • Novartis Investigative Site
    Manila, 1000, Philippines
  • Novartis Investigative Site
    Quezon City, 1100, Philippines
  • Novartis Investigative Site
    Gdansk, 80-169, Poland
  • Novartis Investigative Site
    Gdansk, 80-847, Poland
  • Novartis Investigative Site
    Katowice, 40-752, Poland
  • Novartis Investigative Site
    Poznan, 60-693, Poland
  • Novartis Investigative Site
    Wroclaw, 51-162, Poland
  • Novartis Investigative Site
    Cape Town, 7500, South Africa
  • Novartis Investigative Site
    Cape Town, 7925, South Africa
  • Novartis Investigative Site
    Gatesville, 7764, South Africa
  • Novartis Investigative Site
    Chia-Yi, 600, Taiwan
  • Novartis Investigative Site
    Chiayi, Taiwan
  • Novartis Investigative Site
    Niaosong Township, 83301, Taiwan
  • Novartis Investigative Site
    Taichung, 40447, Taiwan
  • Novartis Investigative Site
    Taipei County, Taiwan
09

References and documents

Publications

  • Chapman KR, Beeh KM, Beier J, Bateman ED, D'Urzo A, Nutbrown R, Henley M, Chen H, Overend T, D'Andrea P. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med. 2014 Jan 17;14:4. doi: 10.1186/1471-2466-14-4. PubMed 24438744 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2012
First posted
Jun 7, 2012
Start
Jun 2012
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Apr 23, 2014
Last update
Apr 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01613326
Responsible party
Sponsor
First posted
Jun 7, 2012
Start date
Jun 2012
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Apr 23, 2014
Last update
Apr 23, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion